You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

SLYND Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Slynd patents expire, and when can generic versions of Slynd launch?

Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-five patent family members in twenty-nine countries.

The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.

DrugPatentWatch® Generic Entry Outlook for Slynd

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (drospirenone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SLYND?
  • What are the global sales for SLYND?
  • What is Average Wholesale Price for SLYND?
Drug patent expirations by year for SLYND
Drug Prices for SLYND

See drug prices for SLYND

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for SLYND
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SLYND Tablets drospirenone 4 mg 211367 1 2022-01-07

US Patents and Regulatory Information for SLYND

SLYND is protected by fourteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SLYND

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SLYND

When does loss-of-exclusivity occur for SLYND?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1670
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 11273605
Patent: Pharmaceutical composition comprising drospirenone and contraceptive kit
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2012033391
Patent: kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.
Estimated Expiration: ⤷  Sign Up

Patent: 2019008317
Patent: kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenona
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 03721
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRENONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

Patent: 03062
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRENONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

Patent: 61421
Patent: METHOD OF PROVIDING CONTRACEPTION IN A PATIENT
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 12003685
Patent: Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 40328
Patent: Composición farmacéutica que comprende drospirenona y kit anticonceptivo
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0200155
Estimated Expiration: ⤷  Sign Up

Patent: 0220332
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 22544
Estimated Expiration: ⤷  Sign Up

Patent: 25061
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 88114
Estimated Expiration: ⤷  Sign Up

Patent: 32448
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 12012359
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷  Sign Up

Patent: 15032906
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (DIVISIONAL 2 DE SOLICITUD No. SP-12-12359 PCT)
Estimated Expiration: ⤷  Sign Up

Patent: 15032911
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (DIVISIONAL 1 DE SOLICITUD No. SP-12-12359 PCT)
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 8680
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДРОСПИРЕНОН, И НАБОР ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАЧАТИЯ (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

Patent: 1291372
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДРОСПИРЕНОН, И НАБОР ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАЧАТИЯ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 88114
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRÉNONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

Patent: 32448
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

Patent: 56186
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

France

Patent: C1020
Estimated Expiration: ⤷  Sign Up

Patent: C1031
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 1200336
Patent: COMPOSICIÒN FARMACÈUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷  Sign Up

Patent: 1200336A
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (SOLICITUD DIVISIONAL NO. 1)
Estimated Expiration: ⤷  Sign Up

Patent: 1200336B
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (SOLICITUD DIVISIONAL NO. 2)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 47689
Estimated Expiration: ⤷  Sign Up

Patent: 58176
Estimated Expiration: ⤷  Sign Up

Patent: 000016
Estimated Expiration: ⤷  Sign Up

Patent: 200018
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 10159
Estimated Expiration: ⤷  Sign Up

Patent: 13529665
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 2021523
Estimated Expiration: ⤷  Sign Up

Patent: 2022513
Estimated Expiration: ⤷  Sign Up

Patent: 88114
Estimated Expiration: ⤷  Sign Up

Patent: 32448
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 9952
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷  Sign Up

Patent: 4971
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷  Sign Up

Patent: 12014629
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷  Sign Up

Patent: 19004393
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 5176
Patent: Pharmaceutical composition comprising drospirenone and contraceptive kit
Estimated Expiration: ⤷  Sign Up

Norway

Patent: 20015
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 130780
Patent: COMPOSION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷  Sign Up

Patent: 161410
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 88114
Estimated Expiration: ⤷  Sign Up

Patent: 32448
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 88114
Estimated Expiration: ⤷  Sign Up

Patent: 32448
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 826
Patent: FARMACEUTSKA KOMPOZICIJA KOJA OBUHVATA DROSPIRENON I KONTRACEPTIVNI KOMPLET (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷  Sign Up

Patent: 027
Patent: FARMACEUTSKA KOMPOZICIJA KOJA OBUHVATA DROSPIRENON ZA UPOTREBU KAO KONTRACEPTIV (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE FOR USE AS A CONTRACEPTIVE)
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 88114
Estimated Expiration: ⤷  Sign Up

Patent: 32448
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1209743
Patent: PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2164693
Estimated Expiration: ⤷  Sign Up

Patent: 2210982
Estimated Expiration: ⤷  Sign Up

Patent: 2539030
Estimated Expiration: ⤷  Sign Up

Patent: 130048227
Patent: PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT
Estimated Expiration: ⤷  Sign Up

Patent: 170085604
Patent: 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit)
Estimated Expiration: ⤷  Sign Up

Patent: 190073598
Patent: 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit)
Estimated Expiration: ⤷  Sign Up

Patent: 210013663
Patent: 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 77886
Estimated Expiration: ⤷  Sign Up

Patent: 08657
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SLYND around the world.

Country Patent Number Title Estimated Expiration
South Korea 102210982 ⤷  Sign Up
Lithuania PA2021523 ⤷  Sign Up
Mexico 2012014629 COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.) ⤷  Sign Up
Eurasian Patent Organization 201291372 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДРОСПИРЕНОН, И НАБОР ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАЧАТИЯ ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SLYND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1380301 2009C/007 Belgium ⤷  Sign Up PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811
3632448 22C1031 France ⤷  Sign Up PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 31332 20191016
3632448 CA 2022 00016 Denmark ⤷  Sign Up PRODUCT NAME: DROSPIRENON; NAT. REG. NO/DATE: 61678 20191016; FIRST REG. NO/DATE: DK 61678 20191016
2588114 2020C/518 Belgium ⤷  Sign Up PRODUCT NAME: DROSPIRENON; AUTHORISATION NUMBER AND DATE: BE548284 20191107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.